John W Gilmore

US Patent:

7074810, Jul 11, 2006

Filed:

Oct 3, 2003

Appl. No.:

10/678331

Inventors:

Bryan W. King - Blue Bell PA, US
James Sheppeck - Newtown PA, US
John L. Gilmore - Yardley PA, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

A61K 31/44
C07D 401/00

US Classification:

514340, 5462724

Abstract:

The present application describes novel hydantoin derivatives of formula (I):.

US Patent:

7211671, May 1, 2007

Filed:

Sep 21, 2004

Appl. No.:

10/946418

Inventors:

James Sheppeck - Newtown PA, US
John L. Gilmore - Yardley PA, US
Xiaohua He - Hockessin DE, US

Assignee:

Bristol Myers Squibb Company - Princeton NJ

International Classification:

C07D 401/12

US Classification:

546152, 5483164, 5483251

Abstract:

The present invention describes novel 1,3-dihydro-imidazol-2-one or 1,3-dihydro-imidazol-2-thione compounds of formula (I):.

US Patent:

7253283, Aug 7, 2007

Filed:

Jan 13, 2005

Appl. No.:

11/035176

Inventors:

David S. Weinstein - East Windsor NJ, US
John L. Gilmore - Yardley PA, US
James Sheppeck - Newtown PA, US
Bingwei Vera Yang - Belle Mead NJ, US
Soong-Hoon Kim - Titusville NJ, US
Wayne Vaccaro - Yardley PA, US

Assignee:

Bristol-Myers Squibb Company - Pricneton NJ

International Classification:

C07D 417/02
C07D 413/02
A61K 31/473

US Classification:

546 99, 546 97, 514295, 514256

Abstract:

Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of formula (I).

US Patent:

7544808, Jun 9, 2009

Filed:

Jul 5, 2007

Appl. No.:

11/773506

Inventors:

David S. Weinstein - East Windsor NJ, US
John L. Gilmore - Yardley PA, US
James Sheppeck - Newtown PA, US
Bingwei Vera Yang - Belle Mead NJ, US
Soong-Hoon Kim - Titusville NJ, US
Wayne Vaccaro - Yardley PA, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

C07D 277/20
A61K 31/425

US Classification:

548185, 548233, 5482654, 5483325, 514371, 514377, 514383, 514398

Abstract:

Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of formula (I).

US Patent:

7569689, Aug 4, 2009

Filed:

Jan 13, 2005

Appl. No.:

11/034652

Inventors:

Jingwu Duan - Yardley PA, US
Bin Jiang - Norristown PA, US
James Sheppeck - Newtown PA, US
John L. Gilmore - Yardley PA, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

A61K 31/498
C07D 417/14

US Classification:

544343, 514250

Abstract:

A class of novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of formula (I).

US Patent:

7605264, Oct 20, 2009

Filed:

Jan 13, 2005

Appl. No.:

11/035290

Inventors:

David S. Weinstein - East Windsor NJ, US
James Sheppeck - Newtown PA, US
John L. Gilmore - Yardley PA, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

A61K 31/439
C07D 417/14

US Classification:

546 63, 5462707, 514286

Abstract:

Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of formula (I).

US Patent:

7625921, Dec 1, 2009

Filed:

Jan 13, 2005

Appl. No.:

11/034822

Inventors:

Jingwu Duan - Yardley PA, US
James Sheppeck - Newtown PA, US
Bin Jiang - Norristown PA, US
John L. Gilmore - Yardley PA, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

A61K 31/4748
C07D 401/14
C07D 417/12

US Classification:

514289, 546 74, 546 63, 514286

Abstract:

A class of novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of formula (I).

US Patent:

8067447, Nov 29, 2011

Filed:

Oct 31, 2007

Appl. No.:

12/513192

Inventors:

James E. Sheppeck - Newtown PA, US
John L. Gilmore - Yardley PA, US
T. G. Murali Dhar - Newtown PA, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

A61K 31/433
A61K 31/416
C07D 285/135
C07D 231/56
C07D 231/40

US Classification:

514363, 514406, 548139, 5483625

Abstract:

Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, and/or AP-1, and/or NF-κB activity including inflammatory and immune diseases, obesity and diabetes having the structure of formula (I), its enantiomers, diastereomers, or a pharmaceutically-acceptable salt, or hydrate, thereof, wherein (Ia) is heterocycle or heteroaryl; J, Ja, E, F, G, Ma, M, Q, Za and Z are as defined herein. Also provided are pharmaceutical compositions and methods of treating inflammatory- or immune-associated diseases and obesity and diabetes employing said compounds.